Netramark Holdings Inc · TSX:AIAI
Netramark — Investor Presentation (January 2024)
26 slides from Netramark's investor presentation, January 2024
Slide 1: Corporate Presentation January 2024
CSE: AIAI CORPORATE PRESENTATION OTCQB: AINMF January 2024 FRA: 8TV
Slide 2: Disclaimer
IMPORTANT – YOU MUST READ THE FOLLOWING BEFORE CONTINUING: The information contained in this CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement presentation has been prepared by NetraMark Holdings Inc. (“NetraMark” or the “Company”) and conta
Slide 3: Risk Factors
RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The risks and uncertainties described herein are not the only ones the Company faces. Additional risks and uncertainties, including those
Slide 4: Our Vision and Goals
The NetraMark vision is to have a material OUR VISION AND GOALS impact on the current 12% clinical trial success rate and serve the pharmaceutical industry’s demands for the efficient development of novel therapeutics and medicines. CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 5: The Team
We have assembled a highly experienced leadership team OFFICERS George Achilleos Josh Spiegel Dr. Joseph Geraci Awards / Partnerships Chief Executive Officer President Chief Technology Officer / Chief Scientific Officer and Director George is a seasoned Business Executive with 25+ 25-plus years of e
Slide 6: The Pharmaceutical Industry
The AI pharmaceutical space THE PHARMACEUTICAL INDUSTRY Key areas of application: 1. Identifying novel /Repurposing existing molecules ideally suited to address disease 2. Patient Matching/Recruitment 3. Clinical trial de-risking CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 7: The Opportunity
We believe there is significant opportunity to improve the clinical trial process and reduce the associated cost BASIC DRUG PRE- FDA POST-APPROVAL CLINICAL TRIALS RESEARCH & RESEARCH DISCOVERY CLINICAL REVIEW MONITORING PHASE I PHASE II PHASE III PHASE IV From drug discovery through THE OPPORTUNITY
Slide 8: The Market
The clinical trial market is robust, growing and large The number of cumulative clinical trials over time1 Number of interventional clinical studies, past 12 months1 450,000 399,522 400,000 2,500 362,500 350,000 325,771 293,254 2,000 300,000 262,299 250,000 233,124 1,500 205,335 2,300 200,000 181,22
Slide 9: Clinical Trial Problems & Risks
The core issues • Early phase trials not necessarily predictive of later phase CLINICAL TRIAL PROBLEMS & RISKS pivotal studies • Observed or potential adverse events can derail programs • Lack of separation in indications known for placebo response • Unexpected results for diseases with heterogenous
Slide 10: The Challenge of Using AI for Clinical Trials
The challenge of using AI for clinical trials THE CHALLENGE FOR AI The challenge centers around the ability to apply AI methods to small datasets and extract statistically significant insights that can be utilized to enrich future studies and reduce the associated costs CSE: AIAI OTCQB: AINMF FRA: 8
Slide 11: Over 95% of Trials Have Less Than 1,000 Participants
Over 95% of trials have less than 1,000 participants Extracting statistically relevant findings from smaller population data sets to provide actionable insights for clinical trials is challenging. HEA LSLOELNUGTEI OFNO R A I Cumulative # of trials by anticipated # of participants (1999 – 2021)* 1-10
Slide 12: Traditional View of Existing Data
Traditional view of existing data Unless there is a massive effect size in the ETHODS data or a large sample size, traditional methods have limitations TA E ADLAM Traditional methods: • T-Tests and ANOVA HN • Chi-Square Test IA T R A D I TT • Logistic Regression • Linear Regression • Feature selecti
Slide 13: The NetraMark Approach – Attractor AI
The Attractor AI view of Genetic A NetraMark innovation - Attractor AI Non Small Cell Lung Cancer data THE NETRAMARK APPROACH – ATTRACTOR AI At the core of NetraAI exists a new paradigm: Attractor AI NetraAI will identify patients that require different treatments, react differently to placebo or to
Slide 14: Go To Market – Approach / Use Case / Pipeline
Go To Market – Approach / Use Case / Pipeline CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 15: The Go To Market Approach
The Target Engagement Biotech or pharma company programs with clinical data in an indication of experience in these areas: • Oncology • Neurology THE GO TO MARKET APPROACH • Psychiatry • Metabolic • Rare & Orphan Disorders The Target Audience Leverage high level relationships & attend disease specif
Slide 16: The NetraMark Workflow
Step 1 The NetraMark Data preparation and ingestion Workflow Various data formats provided by the sponsor are prepared and ingested into a Sponsor specific instance of NetraAI Step 2 Step 3 Step 4 Step 5 THE WORKFLOW NetraAI NetraPlay AutoPlay Insight Tables NetraAI uses NetraPlay is an Augmented Au
Slide 17: Use Case – Schizophrenia Trial
Sponsor Brief: Phase IIa Schizophrenia Trial Project objectives Data included clinical scales: CGI-S, LOF, Strauss- • Characterize patient response to optimize USE CASE – SCHIZOPHRENIA TRIAL Carpenter Level of Functioning; mITT, PANSS, and in addition physiological measurements including heart rate,
Slide 18: Data Preparation and Ingestion
Data Preparation and Ingestion The process 1 • Data transferred to NetraMark via preferred Transcriptomics Sponsor compliant method HRENIA TRIAL Proteomics Genomics Clinical Trial Data • Specialized software is utilized to convert various types of data (e.g., transcriptomic, scales, imaging, Methyla
Slide 19: NetraMark AI Analysis: Placebo Response Hypothesis
NetraMark AI Analysis Placebo Response Hypothesis NetraAI HRENIA TRIAL The Attractor AI based NetraAI was able to identify subpopulations of patients consisting of nearly 50% of placebo responders that were highly explainable through a set of Placebo OTPA responders variables. ZA Placebo E ID non-re
Slide 20: NetraMark AI Analysis: Drug Response Hypothesis
NetraMark AI Analysis Drug Response Hypothesis NetraAI HRENIA TRIAL The Attractor AI based NetraAI was able to identify subpopulations of patients consisting of nearly 37.5 % of drug non-responders Drug that were highly explainable through a set of non-responders OTPA variables. ZA E ID These insigh
Slide 21: Using NetraAI to Drive Better Results in Late Phase Studies
Using NetraAI to drive better results in late phase studies By Combining NetraAI Hypotheses A Roadmap To Maximize Endpoint Effect Size is Generated USE CASE – SCHIZOPHRENIA TRIAL p = .04 • Assumption - a scaled-up version of the clinical trial consisting of 100 people in both the active and placebo
Slide 22: Use Case – Schizophrenia Trial
USE CASE – SCHIZOPHRENIA TRIAL
Slide 23: The Business Model
Current Year Focus Current Results THE BUSINESS MODEL 65+ Leads in the sales pipeline Expanding the sales pipeline 30+ Channel partner discussions Leverage leadership pharmaceutical network Pharma Targeting outreach Engagement Value Range: $100K - $500K CDN Aggressive conference schedule Gross Margi
Slide 24: The Market Comps
The Pharmaceutical AI sector is producing high valuation multiples Comparison Estimated Revenue Pre-Money Valuation Valuation / Rev Multiple Owkin1 2020 ~ $12.15M Nov 2021 ~ $1.12B ~ 92X ConcertAI1 2022 ~ $53M Mar 2022 ~ $1.75B ~ 33X THE MARKET COMPS AITIA2 ~ $14M Jan 2020 ~ $120M ~ 8.6X PathAI3 ~ $
Slide 25: Thank you
Thank you For more information, please contact george@netramark.com CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 26: Statutory Rights of Action
STATUTORY RIGHTS OF ACTION In certain circumstances, purchasers resident in certain provinces of Canada, are provided with a remedy for rescission or damages, and (g) in no case will the amount recoverable in such action exceed the price at which the securities were sold to you. The foregoing is or
NetraMark Holdings — Investor Presentation (January 2024) on 6ix